Oncoscience journal
MISSION
Oncoscience's mission is to cover the rapidly growing field of cancer research. We aim to focus on emergent topics not currently covered by other journals.
Oncoscience has also a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.
Launched in 2014, Oncoscience is a peer-reviewed, traditional-style, bi-monthly journal with free access. Oncoscience also has a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.
As a traditional journal, Oncoscience publishes papers online in issues with page numbers. Each issue/paper can be printed upon special request.
All Oncoscience content is archived in PubMed Central.
The publisher also maintains the journal's own digital archive.
Oncoscience is indexed/abstracted in PubMed, PubMed Central, Scopus (Oncology category), and EMBASE. In 2018, Oncoscience was invited to participate and is now indexed in META, a world-renowned database of scientific literature.
ARCHIVING & INDEXING
- PubMed
- PubMed Central
- Scopus (Oncology category)
- EMBASE
- META (Chan Zuckerberg Initiative)
- Dimensions (Digital Science)
Oncoscience covers the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. Cancer research has entered a new phase in which the convergence of information from different disciplines (e.g., cancer biology, bioinformatics, chemistry, and drug design among others) is beginning to provide new insight into tumor development and cancer treatment.
To capture the key elements of this phase, Oncoscience covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, as well as their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, the journal covers the niche of interdisciplinary articles that bring together cancer biology, chemistry, and drug design.
Oncoscience also regularly publishes Editorials on emergent topics and commentaries on highly visible papers published in other journals.
Its international Editorial Board includes 65 members from different countries, including the USA (predominantly), United Kingdom, Sweden, France, Denmark and Spain. All are highly cited authors, professors at leading universities, and are supported by numerous NIH grants. The Editorial Board includes 20 members of the National Academy of Sciences (USA), 6 Lasker Award recipients (Brian Druker, Andrew Schally, Alexander Varshavsky, Stephen J. Elledge, William G. Kaelin,Jr., and Greg L. Semenza) and a Nobel Prize winner (Andrew Schally).
When general population speak of today’s medicine, precision plays one of the most important roles and human lives are literally dependent on it. Hereby, any researches pertaining to medicine are necessary to meet the highest standards. The issue today is that any outcomes of researches can be shared online and used as a reference without being thoroughly verified and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this problem and decided to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been founded back in 2010. The key principle of this journal is based on Altmetric scores that are used as a quality measure. That helps both readers and authors to verify publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a complete publications list with respective scores above 100 as well as reports discussed previously. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it provides the necessary assistance to anyone, who has interest in oncology.
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This paper was released back in 2018 by Oncotarget and written by various experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The publication has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are willing to understand the very meaning of it. Based on the Altmetric website, the score relates to “how many people have been exposed to and engaged with a scholarly output.” Hence, the paper about melanoma, was used for citations in various news articles 69 times. In addition, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s study with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a brief overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is proud to have the chance to share with online readers this highly appreciated and high-quality information, that is trustworthy and reliable.
https://link.springer.com/article/10.1007/s11192-018-2949-6
Comments
Post a Comment